SLNO FY2025 EPS Estimate Decreased by Cantor Fitzgerald

Soleno Therapeutics, Inc. (NASDAQ:SLNO) – Equities researchers at Cantor Fitzgerald decreased their FY2025 earnings per share estimates for shares of Soleno Therapeutics in a report released on Thursday, May 8th. Cantor Fitzgerald analyst K. Kluska now forecasts that the company will post earnings of ($3.44) per share for the year, down from their previous forecast of ($2.85). Cantor Fitzgerald currently has a “Overweight” rating and a $123.00 target price on the stock. The consensus estimate for Soleno Therapeutics’ current full-year earnings is ($3.72) per share.

Several other research analysts have also recently weighed in on SLNO. HC Wainwright restated a “buy” rating and issued a $100.00 price target on shares of Soleno Therapeutics in a research note on Tuesday, April 15th. Lifesci Capital upgraded shares of Soleno Therapeutics to a “strong-buy” rating in a research note on Tuesday, February 4th. Stifel Nicolaus raised their price target on shares of Soleno Therapeutics from $74.00 to $108.00 and gave the company a “buy” rating in a report on Friday, March 28th. Laidlaw lifted their price target on shares of Soleno Therapeutics from $75.00 to $105.00 and gave the stock a “buy” rating in a research note on Thursday, March 27th. Finally, Piper Sandler lifted their price target on shares of Soleno Therapeutics from $93.00 to $145.00 and gave the stock an “overweight” rating in a research note on Thursday, April 24th. Eight analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Soleno Therapeutics presently has an average rating of “Buy” and an average target price of $106.78.

Soleno Therapeutics Stock Up 0.7%

Shares of NASDAQ SLNO opened at $76.77 on Monday. The firm has a market cap of $3.83 billion, a P/E ratio of -23.12 and a beta of -2.67. Soleno Therapeutics has a twelve month low of $36.93 and a twelve month high of $80.99. The company has a 50 day moving average of $63.25 and a 200 day moving average of $54.37.

Soleno Therapeutics (NASDAQ:SLNO) last issued its earnings results on Wednesday, May 7th. The company reported ($0.95) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.14) by $0.19.

Hedge Funds Weigh In On Soleno Therapeutics

A number of hedge funds have recently modified their holdings of the company. Moody Aldrich Partners LLC boosted its position in shares of Soleno Therapeutics by 0.7% in the first quarter. Moody Aldrich Partners LLC now owns 29,810 shares of the company’s stock worth $2,130,000 after purchasing an additional 196 shares during the period. Avanza Fonder AB grew its position in shares of Soleno Therapeutics by 14.8% during the first quarter. Avanza Fonder AB now owns 1,951 shares of the company’s stock worth $144,000 after purchasing an additional 251 shares in the last quarter. SG Americas Securities LLC raised its stake in Soleno Therapeutics by 8.6% during the 1st quarter. SG Americas Securities LLC now owns 4,397 shares of the company’s stock valued at $314,000 after purchasing an additional 350 shares during the period. Corebridge Financial Inc. lifted its holdings in Soleno Therapeutics by 2.9% in the 4th quarter. Corebridge Financial Inc. now owns 12,720 shares of the company’s stock worth $572,000 after purchasing an additional 357 shares in the last quarter. Finally, Summit Investment Advisors Inc. lifted its holdings in Soleno Therapeutics by 24.2% in the 4th quarter. Summit Investment Advisors Inc. now owns 2,677 shares of the company’s stock worth $120,000 after purchasing an additional 522 shares in the last quarter. 97.42% of the stock is currently owned by institutional investors.

Insider Activity at Soleno Therapeutics

In related news, insider Patricia C. Hirano sold 128,653 shares of Soleno Therapeutics stock in a transaction on Thursday, March 27th. The stock was sold at an average price of $68.32, for a total transaction of $8,789,572.96. Following the transaction, the insider now directly owns 55,789 shares in the company, valued at approximately $3,811,504.48. The trade was a 69.75% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Bhatnagar Anish sold 699,095 shares of Soleno Therapeutics stock in a transaction that occurred on Thursday, March 27th. The shares were sold at an average price of $67.62, for a total transaction of $47,272,803.90. Following the transaction, the chief executive officer now directly owns 577,076 shares in the company, valued at $39,021,879.12. This represents a 54.78% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 942,672 shares of company stock worth $64,058,781. 12.30% of the stock is owned by company insiders.

About Soleno Therapeutics

Soleno Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.